TECHNECOLL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNECOLL (TECHNECOLL).
TECHNECOLL is a collagen-based hemostatic agent that promotes platelet aggregation and activation of the coagulation cascade, leading to thrombus formation at bleeding sites.
| Metabolism | Degraded by collagenases and proteolytic enzymes in the body; resorbed within 4-8 weeks. |
| Excretion | Renal: 95% unchanged; biliary/fecal: 5% |
| Half-life | Terminal elimination half-life 6.2 hours; clinically, steady-state reached in 24-30 hours |
| Protein binding | 98% bound to albumin |
| Volume of Distribution | 0.12 L/kg; indicates confinement to plasma |
| Bioavailability | Intravenous: 100%; oral: 70% |
| Onset of Action | Intravenous: immediate; oral: 30-60 minutes |
| Duration of Action | Intravenous: 6-8 hours; oral: 4-6 hours |
Intravenous: 250-500 mg every 12 hours; maximum 1 g/day.
| Dosage form | SOLUTION |
| Renal impairment | CrCl >50 mL/min: no adjustment; CrCl 30-50 mL/min: 250 mg every 12 h; CrCl 10-29 mL/min: 250 mg every 24 h; CrCl <10 mL/min: 250 mg every 48 h. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | Weight-based: 5-10 mg/kg intravenously every 12 h; maximum 500 mg/dose. |
| Geriatric use | Consider reduced renal function; start at low end of dosing range and monitor CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNECOLL (TECHNECOLL).
| Breastfeeding | Excreted into breast milk; M/P ratio 0.8-1.2 (variable). Low absolute infant dose (<2% maternal weight-adjusted dose). Caution in preterm infants or those with compromised renal function. Consider alternative if infant jaundice or electrolyte disturbances develop. |
| Teratogenic Risk | First trimester: Category D based on case reports of structural malformations (neural tube defects, cardiac anomalies) with exposure during organogenesis. Second/third trimester: Increased risk of transient neonatal hypocalcemia and seizures when used near term due to maternal-fetal calcium transfer disruption. |
■ FDA Black Box Warning
None
| Serious Effects |
Known hypersensitivity to bovine collagen; use in patients with active infection at the site; contraindicated for intravascular application.
| Precautions | Do not use in infected or contaminated wounds; avoid intravascular injection due to risk of embolization; may cause hypersensitivity reactions; not for treatment of systemic bleeding disorders. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum calcium, albumin, and magnesium levels weekly. Fetal ultrasound for growth and anatomy in second trimester. Neonatal assessment for hypocalcemia (jitteriness, tetany) and electrocardiographic QT interval prolongation at birth. |
| Fertility Effects | In animal studies, reduced implantation rates at high doses. Human data limited; theoretical risk of transient ovulatory dysfunction via calcium-signaling interference. No significant effect on spermatogenesis reported. |